Streptokinase

Identification

Summary

Streptokinase is a purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.

Generic Name

Streptokinase

DrugBank Accession Number

DB00086

Background

Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.

Type

Biotech

Groups

Approved, Investigational

Biologic Classification

Protein Based Therapies
Thrombolytic agents

Protein Structure

Protein Chemical Formula

C₂₁₀₀H₃₂₇₈N₅₆₆O₆₆₉S₄

Protein Average Weight

47286.7 Da

Sequences

>Streptokinase Sequence DB00086
MKNYLSFGMFALLFALTFGTVNSVQAIAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDIS
LKFFEIDLTSRPAHGGKTEQGLSPKSKPFATDSGAMSHKLEKADLLKAIQEQLIANVHSN
DDYFEVIDFASDATITDRNGKVYFADKDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQ
AKSVDVEYTVQFTPLNPDDDFRPGLKDTKLLKTLAIGDTITSQELLAQAQSILNKNHPGY
TIYERDSSIVTHDNDIFRTILPMDQEFTYRVKNREQAYRINKKSGLNEEINNTDLISEKY
YVLKKGEKPYDPFDRSHLKLFTIKYVDVDTNELLKSEQLLTASERNLDFRDLYDPRDKAK
LLYNNLDAFGIMDYTLTGKVEDNHDDTNRIITVYMGKRPEGENASYHLAYDKDRYTEEER
EVYSYLRYTGTPIPDNPNDK

Download FASTA Format

Synonyms

• Estreptoquinasa
• Streptochinasi
• Streptococcal fibrinolysin
• Streptokinase
• Streptokinasum

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

For the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Management of	Acute myocardial infarction (ami)		••••••••••••			•••••••••• ••••••• ••• ••••••••
Management of	Acute myocardial infarction (ami)		••••••••••••			•••••••••
Adjunct therapy in treatment of	Acute myocardial infarction (ami)		••••••••••••			•••••••••
Treatment of	Acute myocardial infarction (ami)		••••••••••••			•••••••••
Treatment of	Acute massive pulmonary embolism		••••••••••••			•••••••••• ••••••• ••• ••••••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Streptokinase creates an active complex which promotes the cleavage of the Arg/Val bond in plasminogen to form the proteolytic enzyme plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.

Mechanism of action

Plasminogen is an inactive molecule that becomes activated to plasmin when the Arg/Val bond is cleaved. Plasmin breaks down fibrin clots created by the blood clotting cascade. Streptokinase forms a highly specific 1:1 enzymatic complex with plasminogen which converts inactive plasminogen molecules into active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins. This in turn leads to the degradation of blood clots.

Target	Actions	Organism
APlasminogen	activator	Humans
UProteinase-activated receptor 1	activator	Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Pathway	Category
Streptokinase Action Pathway	Drug action

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abaloparatide	The risk or severity of adverse effects can be increased when Streptokinase is combined with Abaloparatide.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Streptokinase.
Acebutolol	The risk or severity of adverse effects can be increased when Streptokinase is combined with Acebutolol.
Aceclofenac	The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Streptokinase.
Acemetacin	The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Acemetacin.

Food Interactions

• Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Kabikinase - Pws 1500000units/vial	Powder, for solution	1500000 unit / vial	Intracoronary; Intravenous	Pharmacia & Upjohn Inc	1995-12-31	2001-07-30
Kabikinase - Pws 250000 Unit/vial	Powder, for solution	250000 unit / vial	Intracoronary; Intravenous	Pharmacia & Upjohn Inc	1995-12-31	1999-08-12
Kabikinase - Pws 750000units/vial	Powder, for solution	750000 unit / vial	Intracoronary; Intravenous	Pharmacia & Upjohn Inc	1995-12-31	2001-07-30
Streptase	Powder, for solution	1500000 unit / vial	Intracoronary; Intravenous	Csl Behring	1994-12-31	2012-02-22
Streptase	Powder, for solution	250000 unit / vial	Intracoronary; Intravenous	Csl Behring	1994-12-31	2012-02-22

Categories

ATC Codes

B01AD01 — Streptokinase

• B01AD — Enzymes
• B01A — ANTITHROMBOTIC AGENTS
• B01 — ANTITHROMBOTIC AGENTS
• B — BLOOD AND BLOOD FORMING ORGANS

B06AA55 — Streptokinase, combinations

• B06AA — Enzymes
• B06A — OTHER HEMATOLOGICAL AGENTS
• B06 — OTHER HEMATOLOGICAL AGENTS
• B — BLOOD AND BLOOD FORMING ORGANS

Drug Categories

• Agents causing angioedema
• Amino Acids, Peptides, and Proteins
• Anticoagulants
• Blood and Blood Forming Organs
• Blood Proteins
• Cardiovascular Agents
• Endopeptidases
• Enzymes
• Enzymes and Coenzymes
• Fibrin Modulating Agents
• Fibrinolytic Agents
• Hematologic Agents
• Hydrolases
• Hypotensive Agents
• Peptide Hydrolases
• Plasminogen Activators
• Proteins
• Streptokinase, antagonists & inhibitors

Chemical TaxonomyProvided by Classyfire

Description

Not Available

Kingdom

Organic Compounds

Super Class

Organic Acids

Class

Carboxylic Acids and Derivatives

Sub Class

Amino Acids, Peptides, and Analogues

Direct Parent

Peptides

Alternative Parents

Not Available

Substituents

Not Available

Molecular Framework

Not Available

External Descriptors

Not Available

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

8X1OXL3SNU

CAS number

9002-01-1

References

Synthesis Reference

Lawrence Isaac Galler, "Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy." U.S. Patent US6087332, issued July, 1997.

US6087332

General References

Not Available

External Links

UniProt

P00779

Genbank

K02986

PubChem Substance

46505625

RxNav

10106

ChEMBL

CHEMBL2108147

Therapeutic Targets Database

DAP001198

PharmGKB

PA164754919

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Streptokinase

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Acute Coronary Syndrome (ACS) / Acute Myocardial Infarction (AMI) / Reperfusion Injury	1
4	Completed	Treatment	Acute Myocardial Infarction (AMI)	1
4	Completed	Treatment	Pulmonary Embolism / Pulmonary Thromboembolism	1
4	Unknown Status	Treatment	Acute Tracheobronchitis / Acute Upper Respiratory Infections	1
4	Unknown Status	Treatment	Pleural Effusions	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

• Pfizer Inc.

Dosage Forms

Form	Route	Strength
Injection, powder, for solution	Intravenous	1500 IU
Injection, powder, for solution	Intravenous	750 IU
Injection, powder, lyophilized, for solution	Intravenous	150000 IU
Injection, powder, lyophilized, for solution	Parenteral	100000 IU
Injection, powder, lyophilized, for solution	Intravenous	250000 IU
Injection, powder, for solution	Intravenous
Injection, powder, lyophilized, for solution	Parenteral	1500000 IU
Injection, powder, lyophilized, for solution	Parenteral	250000 IU
Injection, powder, lyophilized, for solution	Parenteral	750000 IU
Powder, for solution	Intracoronary; Intravenous	1500000 unit / vial
Powder, for solution	Intracoronary; Intravenous	250000 unit / vial
Powder, for solution	Intracoronary; Intravenous	750000 unit / vial
Powder, for solution	Intravenous	1500000 unit / vial
Powder, for solution	Intravenous	250000 unit / vial
Powder, for solution	Intravenous	750000 unit / vial
Powder		000 IU

Prices

Not Available

Patents

Not Available

Properties

State

Liquid

Experimental Properties

Property	Value	Source
hydrophobicity	-0.728	Not Available
isoelectric point	5.12	Not Available

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Plasminogen

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Activator

General Function

Serine-type peptidase activity

Specific Function

Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In...

Gene Name

PLG

Uniprot ID

P00747

Uniprot Name

Plasminogen

Molecular Weight

90568.415 Da

References

1. Caballero AR, Lottenberg R, Johnston KH: Cloning, expression, sequence analysis, and characterization of streptokinases secreted by porcine and equine isolates of Streptococcus equisimilis. Infect Immun. 1999 Dec;67(12):6478-86. [Article]
2. Alessi MC, Juhan-Vague I: [Thrombolytics and their use]. Rev Prat. 1999 Oct 1;49(15):1654-8. [Article]
3. Chaudhary A, Vasudha S, Rajagopal K, Komath SS, Garg N, Yadav M, Mande SC, Sahni G: Function of the central domain of streptokinase in substrate plasminogen docking and processing revealed by site-directed mutagenesis. Protein Sci. 1999 Dec;8(12):2791-805. [Article]
4. Parry MA, Zhang XC, Bode I: Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem Sci. 2000 Feb;25(2):53-9. [Article]
5. Korol'chuk VI, Makohonenko IeM, Sederkhol'm-Vil'iams SA: [Plasminogen binding with decapeptide and polypeptide fragments of streptokinase]. Ukr Biokhim Zh (1999). 1999 Sep-Oct;71(5):51-8. [Article]
6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Details2. Proteinase-activated receptor 1

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Activator

General Function

Thrombin receptor activity

Specific Function

High affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelets activation and in vascular development.

Gene Name

F2R

Uniprot ID

P25116

Uniprot Name

Proteinase-activated receptor 1

Molecular Weight

47439.83 Da

References

1. McRedmond JP, Harriott P, Walker B, Fitzgerald DJ: Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. Blood. 2000 Feb 15;95(4):1301-8. [Article]
2. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR: Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999 Mar;103(6):879-87. [Article]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 13, 2005 13:24 / Updated at January 02, 2024 23:41